Lupin announced the completion of a PAI (Prior Approval Inspection) carried out by the United States Food and Drug Administration (USFDA) at its Nagpur oral solid dosage manufacturing facility.
The inspection was carried out between 06 January 2020 and 10 January 2020.
The inspection closed with two 483 observations.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)